• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, January 22, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Publication details IDRI’s promising leprosy vaccine candidate

Bioengineer by Bioengineer
April 26, 2018
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A publication in Nature Partner Journals (npj) Vaccines indicates that post-exposure prophylaxis with LepVax, IDRI's leprosy vaccine candidate, not only appears safe but, unlike BCG (a tuberculosis vaccine that provides some protection against leprosy), alleviates and delays the neurologic disruptions caused by Mycobacterium leprae infection in nine-banded armadillos. This is an important finding because armadillos are the only other host of M. leprae that closely recapitulates many of the structural, physiological and functional aspects of leprosy observed in humans, including progressive and irreversible nerve damage.

Characterized by the World Health Organization as a "neglected tropical disease," leprosy (also known as Hansen's disease) is caused by Mycobacterium leprae. Nearly a quarter of a million people are diagnosed with leprosy each year, with the infection progressing to cause disfiguration of the skin and mucous membranes as well as progressive and irreversible nerve damage. While drug therapy exists for leprosy, it must be taken for many months, has many side effects and often is given too late to prevent the damage caused by the bacterial infection that leads to lifelong disability.

"This report demonstrates the selection and advancement of the first defined subunit vaccine – LepVax — developed specifically for leprosy," said Malcolm Duthie, PhD, a senior scientist at IDRI. IDRI and The National Hansen's Disease Laboratories (NHDP), under a research agreement with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, conducted mouse experiments to demonstrate that the vaccine is immunogenic and can interrupt M. leprae infection. They also developed cutting edge neurological methods in nine-banded armadillos that were used to evaluate the effect of LepVax on nerve injury as an innovative advance to the field. "Our results indicate that post-exposure immunization in nine-banded armadillos was not only safe but limited and delayed nerve damage," Duthie added.

In stark contrast to BCG, which precipitated rapid and severe motor nerve conduction abnormalities in previously infected armadillos, motor nerve injury was appreciably delayed in armadillos treated three times at monthly intervals with LepVax. The data supported a successful Investigational New Drug (IND) application with the U.S. Food & Drug Administration, allowing advancement of LepVax into a Phase 1 clinical trial in humans in the U.S.

###

"These data highlight the need for continued leprosy research and the importance of both private and public funding as we seek new solutions for neglected tropical diseases, such as leprosy," said Duthie. This research was funded by grants from the American Leprosy Missions, Order of Malta (MaltaLep), The Heiser Program for Research in Leprosy and Tuberculosis of The New York Community Trust, Renaissance Health Service Corporation, and a National Institutes of Health, National Institute of Allergy and Infectious Diseases supported interagency agreement with the Health Resources and Services Administration's National Hansen's Disease Program (AAI15006-004-00000).

About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit http://www.idri.org.

Media Contact

Lee Schoentrup
[email protected]
206-858-6064

http://www.idri.org

http://www.idri.org/publication-details-promising-leprosy-vaccine/

Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

Why so few black skiers and ballet dancers?

January 22, 2021
IMAGE

Navigating uncertainty: Why we need decision theory during a pandemic

January 22, 2021

Mitochondrial mutation increases the risk of diabetes in Japanese men

January 21, 2021

New study: nine out of ten US infants experience gut microbiome deficiency

January 21, 2021
Next Post

In multiple myeloma, different types of blood biopsies match up well with bone marrow tests

Solanine in potatoes: Green and strongly germinating potato tubers should be sorted out

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • People living with HIV face premature heart disease and barriers to care

    65 shares
    Share 26 Tweet 16
  • New drug form may help treat osteoporosis, calcium-related disorders

    40 shares
    Share 16 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

GeneticsPublic HealthClimate ChangecancerMaterialsBiologyCell BiologyMedicine/HealthTechnology/Engineering/Computer ScienceInfectious/Emerging DiseasesEcology/EnvironmentChemistry/Physics/Materials Sciences

Recent Posts

  • Why so few black skiers and ballet dancers?
  • Navigating uncertainty: Why we need decision theory during a pandemic
  • Combined river flows could send up to 3 billion microplastics a day into the Bay of Bengal
  • New combination of immunotherapies shows great promise for treating lung cancer
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In